Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Starts Construction on Large Shanghai CDMO Facility

publication date: Nov 23, 2018

WuXi Biologics has begun construction of a 1.6 million square foot global innovation center in Shanghai's Fengxian district. The company, which did not release an estimated cost for the facility, said its newest Shanghai facility would eventually house 3000 scientists. The building will integrate biologics discovery, development, clinical and commercial manufacturing. In a two-month period earlier this year, WuXi Biologics announced it would build four new manufacturing plants around the globe at a total of cost of nearly $800 million. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.